

**The Centers for Medicare & Medicaid Services (CMS)  
Internal Healthcare Common Procedure Coding System (HCPCS) Decisions  
2017-2018 HCPCS Coding Cycle**

Notice of Discontinuation of Level II HCPCS Code Effective December 31, 2017:

CMS established code A9599 “Radiopharmaceutical, Diagnostic, for Beta-amyloid Positron Emission Tomography (PET) Imaging, Per Study Dose, Not Otherwise Specified” effective 1/1/2014 to identify Beta Amyloid PET tracers not identified in other codes.

CMS established 2 new codes A9597 “Positron Emission Tomography Radiopharmaceutical, Diagnostic, For Tumor Identification, Not Otherwise Classified” and A9598 “Positron Emission Tomography Radiopharmaceutical, Diagnostic, For Non-Tumor Identification, Not Otherwise Classified”, effective 1/1/2017; to create a distinction between use for tumor and non-tumor identification. These new codes obviate the need for code A9599 and as such, CMS proposes to discontinue code A9599 effective 12/31/2017.

**Comments on this coding action may be submitted to [HCPCS@cms.hhs.gov](mailto:HCPCS@cms.hhs.gov) (please put “discontinued code comment” in subject line) and will be considered if they are received by no later than 5pm on July 21, 2016.**